Developed under the auspices of the University of Glasgow supported by unrestricted educational grants from Pfizer Italia S.r.l., R-Pharm CJSC and Eli Lilly.
The use of cytokine inhibitors as a treatment for inflammatory diseases is at the forefront of scientific development and is beginning to move from clinical trials into practice. With the approval of tofacitinib in many countries and other agents moving into phase II/III trials, staying current with the ongoing research is critical to clinical practice. The development of these agents brings in new targeted therapy and has the potential of great benefit to patients. This course outlines recent developments in cytokine signalling and IL-6 inhibition and show how these developments may come to clinical fruition over the coming years.
By following this programme, you will be able to:
Professor Iain B. McInnes
Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.
|IL-6 Inhibitors: Clinical Data Update ACR 2016||
Professor Tsutomu Takeuchi
Professor of Rheumatology, Keio University School of Medicine,
Professor Tsutomu Takeuchi completed his medical education at Keio University School of Medicine and is currently Professor of Medicine in the Department of Internal Medicine at the same institution. His major research interests are molecular pathogenesis of systemic autoimmune diseases, targeted therapy in systemic autoimmune diseases, and prediction of therapeutic response. Professor Takeuchi has published more than 100 articles in peer-reviewed journals including Arthritis & Rheumatism, Annals of the Rheumatic Diseases, The Journal of Immunology, The Journal of Rheumatology, and The Journal of Clinical Investigation. Professor Takeuchi serves or has served as an editorial board member of the following journals: Rheumatology, Clinical Rheumatology, Clinical Immunology, and Modern Rheumatology. As a reviewer, he is currently serving for Nature Reviews of Immunology, The Lancet, Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Rheumatology, Arthritis Research & Therapy, The Journal of Rheumatology, The Journal of Clinical Rheumatology, APLAR Journal of Rhematology, Modern Rheumatology, The Journal of Immunology, European Journal of Immunology, International Immunology, and The American Journal of Pathology.
|Cytokine Signalling Inhibitors: Clinical Data Update ACR 2016||
Professor Peter Taylor
Norman Collisson Professor of Musculoskeletal Sciences,
Professor Peter Taylor studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge, where he earned his first degree in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on the pathogenesis of arthritis. In October 2011, Professor Taylor was appointed Norman Collisson Chair of Musculoskeletal Sciences at the University of Oxford, and is a Fellow of St. Peter's College, Oxford. He is the Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.
He has specialist clinical interests in novel therapies, rheumatoid and early arthritis. His research expertise is in mechanisms sustaining inflammation and clinical trials of new therapies with development of novel outcome measurements for application in assessment of response to therapy.
Date of preparation: December 2016